The University of Southampton
University of Southampton Institutional Repository

Advances in advanced prostate cancer - the continuing journey

Advances in advanced prostate cancer - the continuing journey
Advances in advanced prostate cancer - the continuing journey
Prior to 2004, the uro-oncology community viewed the management of advanced or metastatic prostate cancer with an air of resigned nihilism. Now, the range of therapeutic options available is the subject of ongoing debate and the British Uro-oncology Group (BUG) is collating oncologist opinions on the future management of castration-sensitive disease. Historically, treatment for metastatic prostate cancer was limited to androgen deprivation therapy (ADT) with the aims of delaying disease progression and palliating symptoms. Patients invariably progressed, developing castration-resistant disease with limited effective therapeutic options.
1464-4096
17-19
Payne, H.
700deed4-1c2c-4227-873b-b700498507f6
Davda, R.
fbef60a5-674e-4f83-b0c0-4878ab4ecad7
Jones, R.
9d9f872b-9caa-442a-aef0-c6f14826ef55
Crabb, S.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Troup, J.
27e5d9f6-796d-4f85-af89-4ef6c10bbfbd
Hughes, S.
d246ca0a-9850-46c6-8f64-a11fa8e51085
Payne, H.
700deed4-1c2c-4227-873b-b700498507f6
Davda, R.
fbef60a5-674e-4f83-b0c0-4878ab4ecad7
Jones, R.
9d9f872b-9caa-442a-aef0-c6f14826ef55
Crabb, S.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Troup, J.
27e5d9f6-796d-4f85-af89-4ef6c10bbfbd
Hughes, S.
d246ca0a-9850-46c6-8f64-a11fa8e51085

Payne, H., Davda, R., Jones, R., Crabb, S., Troup, J. and Hughes, S. (2016) Advances in advanced prostate cancer - the continuing journey. BJU International, 118 (1), 17-19. (doi:10.1111/bju.13350). (PMID:26456636)

Record type: Article

Abstract

Prior to 2004, the uro-oncology community viewed the management of advanced or metastatic prostate cancer with an air of resigned nihilism. Now, the range of therapeutic options available is the subject of ongoing debate and the British Uro-oncology Group (BUG) is collating oncologist opinions on the future management of castration-sensitive disease. Historically, treatment for metastatic prostate cancer was limited to androgen deprivation therapy (ADT) with the aims of delaying disease progression and palliating symptoms. Patients invariably progressed, developing castration-resistant disease with limited effective therapeutic options.

This record has no associated files available for download.

More information

Accepted/In Press date: 11 October 2015
e-pub ahead of print date: 4 November 2015
Published date: July 2016
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 383027
URI: http://eprints.soton.ac.uk/id/eprint/383027
ISSN: 1464-4096
PURE UUID: 53df73f1-b280-4b1e-b002-2c52f18f2ec0
ORCID for S. Crabb: ORCID iD orcid.org/0000-0003-3521-9064

Catalogue record

Date deposited: 10 Nov 2015 11:27
Last modified: 15 Mar 2024 03:16

Export record

Altmetrics

Contributors

Author: H. Payne
Author: R. Davda
Author: R. Jones
Author: S. Crabb ORCID iD
Author: J. Troup
Author: S. Hughes

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×